Text Size

Non-Invasive Measures of Distal Lung Disease in Asthmatics

This study has been completed.
Sponsor:
Information provided by:
Teva Branded Pharmaceutical Products, R&D Inc.
ClinicalTrials.gov Identifier:
NCT00250341
First received: November 4, 2005
Last updated: March 31, 2008
Last verified: March 2008
History of Changes
  Purpose

This is a Phase 4, single center study conducted in mild-to moderate asthmatics.


Condition Intervention Phase
Asthma
 Drug: QVAR
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Asthma
U.S. FDA Resources

Further study details as provided by Teva Branded Pharmaceutical Products, R&D Inc.:

Primary Outcome Measures:
  • High resolution Cat Scans

Estimated Enrollment: 34
Study Start Date: September 2005
Study Completion Date: September 2007
Detailed Description:

The study consists of 3 phases. There are 7 study visits.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18-65 years old
  • Currently using SABA prn or a low-to-moderate persistent asthma

Exclusion Criteria:

  • Tobacco use within 1 year or >= 5 pack years
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00250341

Locations
United States, California
UCLA
Los Angeles, California, United States, 90095
Sponsors and Collaborators
Teva Branded Pharmaceutical Products, R&D Inc.
Investigators
Principal Investigator: Michelle Zeidler, MD University of California, Los Angeles
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00250341     History of Changes
Other Study ID Numbers: IXR-403-4-196
Study First Received: November 4, 2005
Last Updated: March 31, 2008
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
 Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on May 19, 2013